The driver mutations critical to leiomyoma development and progression include MED12 (mediator complex subunit 12), HMGA2 (high mobility group AT-hook 2), FH (fumarate hydratase), and COL4A5/6 (collagen type IV, alpha 5, and alpha 6) [8–11]. This evidence concerns the gene MED12 and leiomyoma.